Halopropane
Jump to navigation
Jump to search
Clinical data | |
---|---|
Trade names | Tebron |
ATC code |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
Chemical and physical data | |
Formula | C3H3BrF4 |
Molar mass | 194.955 g·mol−1 |
3D model (JSmol) | |
| |
|
Halopropane (synonym FHD-3, trade name Tebron) is a halocarbon drug which was investigated as an inhalational anesthetic but was never marketed.[1] Its clinical development was terminated due to a high incidence of cardiac arrhythmias in patients, similarly to the cases of teflurane and norflurane.[2][3][4]
See also
References
- ^ Webster NR, Galley HF (22 August 2013). Landmark Papers in Anaesthesia. OUP Oxford. pp. 70–. ISBN 978-0-19-163319-5.
- ^ Acta anaesthesiologica Belgica. Acta Medica Belgica. 1974.
- ^ Klein SL (1993). A glossary of anesthesia and related terminology. Springer-Verlag. ISBN 978-0-387-97831-4.
- ^ Catcott EJ, Smithcors JF (1973). Progress in canine practice. American Veterinary Publications.
Categories:
- Articles with short description
- Short description matches Wikidata
- Drugs not assigned an ATC code
- Articles without EBI source
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Drugs with no legal status
- Articles containing unverified chemical infoboxes
- General anesthetics
- Organobromides
- Organofluorides
- GABAA receptor positive allosteric modulators
- All stub articles
- Nervous system drug stubs